Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000-2015)
- PMID: 28604100
- DOI: 10.2217/fmb-2016-0200
Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000-2015)
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) is endemic in Greece. CRAB initially emerged in 2000 and since then, carbapenemases still have a crucial role in CRAB appearance, except for a few cases resulting from efflux pump or outer-membrane protein mechanisms. OXA-type carbapenemases present the highest prevalence worldwide and bla OXA-23-like and bla OXA-58-like are the most important genes found; VIM-yielding CRAB have also been detected, while a single CRAB isolate producing NDM has quite recently emerged in Greece. The predominant OXA-23 producers are associated with multilocus sequence typing Pasteur scheme sequence type 2 clonal strains of the international clone II. The emergence of colistin-resistant CRAB has complicated the treatment of such infections and the interpretation of susceptibility data. Infection control measures and adjusted antimicrobial treatment strategies could confine CRAB spread. The aim of this review is to go through the molecular epidemiology of CRAB, in an endemic area and highlight its potential future evolution.
Keywords: Acinetobacter baumannii; OXA-type carbapenemases; carbapenem resistance; molecular epidemiology.
Similar articles
-
A diversity of OXA-carbapenemases and class 1 integrons among carbapenem-resistant Acinetobacter baumannii clinical isolates from Sweden belonging to different international clonal lineages.Microb Drug Resist. 2011 Dec;17(4):545-9. doi: 10.1089/mdr.2011.0089. Epub 2011 Aug 10. Microb Drug Resist. 2011. PMID: 21830948
-
Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II.J Antimicrob Chemother. 2008 Sep;62(3):484-9. doi: 10.1093/jac/dkn205. Epub 2008 May 13. J Antimicrob Chemother. 2008. PMID: 18477708
-
Characterisation and clonal dissemination of OXA-23-producing Acinetobacter baumannii in Tabriz, northwest Iran.Int J Antimicrob Agents. 2012 Jun;39(6):526-8. doi: 10.1016/j.ijantimicag.2012.02.014. Epub 2012 Apr 20. Int J Antimicrob Agents. 2012. PMID: 22521767
-
Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance.Ann Clin Microbiol Antimicrob. 2019 Jan 3;18(1):1. doi: 10.1186/s12941-018-0301-x. Ann Clin Microbiol Antimicrob. 2019. PMID: 30606201 Free PMC article. Review.
-
Carbapenemases in Acinetobacter baumannii. Review of their dissemination in Latin America.Rev Argent Microbiol. 2018 Jul-Sep;50(3):327-333. doi: 10.1016/j.ram.2017.10.006. Epub 2018 Mar 13. Rev Argent Microbiol. 2018. PMID: 29548732 Review.
Cited by
-
Characteristics of the Genetic Spread of Carbapenem-Resistant Acinetobacter baumannii in a Tertiary Greek Hospital.Genes (Basel). 2024 Apr 5;15(4):458. doi: 10.3390/genes15040458. Genes (Basel). 2024. PMID: 38674392 Free PMC article.
-
Development and Clinical Application of a Recombinase Polymerase Amplification-Lateral Flow Strip Assay for Detection of Carbapenem-Resistant Acinetobacter baumannii.Front Cell Infect Microbiol. 2022 May 11;12:876552. doi: 10.3389/fcimb.2022.876552. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35646723 Free PMC article.
-
Major Bloodstream Infection-Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Phase I Report From Kor-GLASS.Front Microbiol. 2022 Jan 6;12:799084. doi: 10.3389/fmicb.2021.799084. eCollection 2021. Front Microbiol. 2022. PMID: 35069503 Free PMC article.
-
Antibiotic Susceptibility Testing and Establishment of Tentative Species-Specific Microbiological Cut-off Values for Bifidobacteria Isolated from Chinese Population.Probiotics Antimicrob Proteins. 2024 Oct;16(5):1657-1672. doi: 10.1007/s12602-023-10128-9. Epub 2023 Jul 29. Probiotics Antimicrob Proteins. 2024. PMID: 37515711
-
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14. Microbiol Spectr. 2024. PMID: 38483164 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
